Three state legislatures have moved forward with dementia-related legislation that includes mandating biomarker testing coverage by insurance plans, creating new memory care licensure and creating a ...

Gov. Kathy Hochul’s Executive Budget would weaken the evidence-based standards in New York’s biomarker testing law, putting ...

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

A Tennessee bill that would require health insurance and TennCare to cover biomarker testing, which gives doctors more ...

Across all cancer types, less than 50% of patients underwent biomarker testing before first-line treatment. Many patients with advanced cancer do not receive guideline-recommended biomarker testing ...

Precision medicine relies on biomarker testing to match therapies to specific cancers, yet many patients remain untested due to standardization issues. Recommendations include educating clinicians, ...

Legislation to improve access to treatment for cancer and amyotrophic lateral sclerosis (ALS) in Pennsylvania was unanimously ...

Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...

It’s common to wait until something feels “off” before making an appointment to see a healthcare provider. But waiting for noticeable symptoms can mean missing the chance to catch health issues early.

At the Tennessee Capitol, patients, advocates and families came prepared on Tuesday afternoon to tell lawmakers something simple: the right test at the right time can save a life.

Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations. Biomarker testing for patients with lung cancer is critical, ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...